RxDoctor Payments Data

Elizabeth Flower, MD

Family Medicine · Windsor, CANPI 1538173141

Payments from drug & device makers

$959in general payments, 2019–2025

Across 32 payments — averaging $29.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$261
  • Novo Nordisk$203
  • AbbVie$165
  • Amgen$159
  • Bayer$63
  • Boehringer Ingelheim$33
  • plus $76 from 3 others

What the payments were for

  • Food & beverage$959100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK4$261
Novo Nordisk6$203
AbbVie12$165
Amgen3$159
Bayer3$63
Boehringer Ingelheim1$33
Lilly USA, LLC1$28
AstraZeneca1$26
Pfizer1$21

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$959 in reported general payments places this provider in the 70th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$341,676
Medicare patients
787
Services billed
3,379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban51$32,436
MounjaroTirzepatide18$18,759
JardianceEmpagliflozin15$16,036
MyrbetriqMirabegron21$13,233
OzempicSemaglutide12$12,641
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,749
Celecoxib218$5,530
SymbicortBudesonide/Formoterol Fumarate11$2,680
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$2,282
Estradiol39$2,085
Minoxidil103$1,929
Irbesartan106$1,874
ValacyclovirValacyclovir Hcl32$1,651
Clonidine16$1,635
Levothyroxine Sodium106$1,622

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$21$32,43651 claims
Lilly USA, LLCMounjaro$28$18,75918 claims
Boehringer IngelheimJardiance$33$16,03615 claims
Novo NordiskOzempic$203$12,64112 claims
GSKTrelegy Ellipta$261$7,74912 claims
AstraZenecaSymbicort$26$2,68011 claims
AbbVieSynthroid$165$1,47414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 10,533 family medicine providers in California.

Other family medicine in Windsor

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →